CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.
News and Events Canadian Medical Imaging Inventory CADTH has released the 2020 Canadian Medical Imaging Inventory (CMII). To view the full report and a summary of key findings, please visit www.cadth.ca/cmii. This is the third iteration of the CMII and it provides a clear picture of current practices and trends in the supply, distribution,...
NEWS AND EVENTS CADTH Symposium 2021 — Call for Abstracts CADTH is now accepting abstracts for the 2021 CADTH Symposium. This year’s theme is Uncertain Times, Imperfect Evidence, and the Imperative to Act. Topics relevant to this theme include, but are not limited to, real-world evidence, virtual health care, and drugs for rare disea...
A previous study demonstrated a high degree of similarity in listing status for primary care drugs across Canada but excluded drugs for specialty care. Assessing formulary harmonization for specialty care medications is critical given that these medications represent a high proportion of overall drug spending. This analysis sought to evaluate fo...
News and Events CADTH’s 2020 Virtual Symposium: A Success! CADTH successfully wrapped up our first-ever virtual Symposium that was held on November 9 and 10, 2020. With more than 1,500 people in attendance, a diverse group of stakeholders gathered to discuss health care decision-making in an age of uncertainty, with health technology expert...
News and Events CADTH Recommends First Gene Therapy Treatment for Rare Form of Childhood Vision Loss On November 16, CADTH recommended that Canada’s federal, provincial, and territorial drug plans (except Quebec) should reimburse, with conditions, voretigene neparvovec (also known as Luxturna and licensed by Novartis Pharmaceutical...
News and Events “There’s Always Evidence…” — A Special Three-Part Webinar January and February 2021 Systematic reviews and meta-analyses are regarded as the gold standard for evidence, but they are not always readily available to inform a specific clinical, policy, or health management decision. In this special three-part webinar serie...
News and Events Call for Nominations CADTH is seeking nominations to its Board of Directors and Expert committees. We’re looking for 15 individuals with significant expertise in the Canadian health care system to join various committees. More information about the roles, the nomination process, honorarium, and time commitments is availabl...
News and Events CADTH Symposium 2021 — Call for Abstracts CADTH is now accepting abstracts for the 2021 CADTH Symposium. This year’s theme is Uncertain Times, Imperfect Evidence, and the Imperative to Act. Topics relevant to this theme include, but are not limited to, real-world evidence, virtual health care, and drugs for rare disea...
Cite as: Marshall J, Blackhouse G, Goeree R, Brazier N, Irvine E, Faulkner L, Dipchand C, O'Brien B. Infliximab for the Treatment of Crohn's Disease: A Systematic Review and Cost-Utility Analysis. Ottawa: Canadian Coordinating Office for Health Technology Assessment (CCOHTA); 2002. Technology report no 24. The Issue Crohn's disease (CD) is a c...